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a  b  s  t  r  a  c  t
Dynamic  perfusion  CT (PCT)  is  an  imaging  technique  for assessing  the  vascular  supply  and  hemodynamics
of  brain  tumors  by  measuring  blood  ﬂow,  blood  volume,  and  permeability-surface  area  product.  These
PCT  parameters  provide  information  complementary  to  histopathologic  assessments  and  have  been  used
for  grading  brain  tumors,  distinguishing  high-grade  gliomas  from  other  brain  lesions,  differentiating
true  progression  from  post-treatment  effects,  and  predicting  prognosis  after  treatments.  In this  review,
the basic  principles  of  PCT  are  described,  and  applications  of PCT  of  brain  tumors  are  discussed.  The
advantages  and  current  challenges,  along  with  possible  solutions,  of  PCT  are presented.
©  2015 Published  by Elsevier  Ireland  Ltd.
1. Introduction
High-grade gliomas (HGGs), the most common primary brain
tumors, are associated with high mortality rates despite aggressive
treatments. The median survival for patients with glioblastomas,
the most aggressive form of gliomas, is only 12–15 months [1].
HGGs are highly vascular tumors, and tumor vascularity is a
determining pathologic hallmark of malignancy [2] that results in
characteristic tumor contrast uptake on contrast-enhanced com-
puted tomography (CT) or magnetic resonance imaging (MRI).
Perfusion imaging provides quantitative information about nor-
mal  brain and tumor physiology that cannot be obtained from
conventional morphological imaging. Dynamic perfusion CT (PCT)
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is an imaging technique that can quantitatively assesses the vascu-
lar supply and permeability of brain tumors by measuring tumor
blood ﬂow (BF), blood volume (BV), and permeability-surface area
product (PS). PCT is well-suited to study brain tumors due to
its widespread availability and low cost, and it is relatively easy
to implement compared to Positron emission tomography (PET)
and MR  perfusion. PCT has been used for grading gliomas, distin-
guishing gliomas from other brain lesions, differentiating tumor
progression from treatment-induced effects, and predicting prog-
nosis after treatments. This review describes the basic principles
of PCT and its applications in neuro-oncology. The advantages and
challenges of PCT as well as their solutions in brain tumor imaging
are presented.
2. Basic principles of PCT
PCT acquires repeated images to track a bolus of iodinated con-
trast agent as it washes into and out of tissue via blood vessels. The
efﬁcient attenuation of X-rays by iodine increases CT image inten-
sity, which is linearly proportional to the iodine concentration [3].
http://dx.doi.org/10.1016/j.ejrad.2015.02.012
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Table 1
A typical brain tumor PCT protocol.
Parameters Speciﬁcations
Contrast agent • Iopamidol
Molecular weight of contrast agent • 777 g/mol (0.777 kDa)
Contrast concentration • 300 mg  Iodine/ml
Contrast dose • 0.8 ml/kg (60–80 ml  in volume for a
typical patient)
Rate of contrast injection • 2–4 ml/s
Scan duration • 2–3 min
Temporal resolution • First phase: 1–2 s/image for 45 s
Second phase: 15 s/image for 105 s
Tube  current • 100–190 mA
Tube voltage • 80 kV
Scan coverage • 4, 8, or 16 cm coverage with
multi-detector CT
• Shuttle mode can achieve whole
brain coverage with 4 or 8 cm
multi-detector CT
Scan start time • 3–5 s after contrast injection
The basis of PCT is to track the delivery of iodine by measuring
changes in image intensity after the arrival of contrast bolus.
Table 1 illustrates a typical brain tumor PCT protocol. It is a two-
phase scan that takes two to three minutes. The ﬁrst phase typically
takes 45 s to capture the ﬁrst pass of contrast and requires rapid
acquisition of CT images (1–2 s/image) for accurate calculations of
BF and BV. The second phase is required for the calculation of PS; it
involves less frequent acquisition of CT images (10–15 s/image) to
reduce imaging dose.
The calculation of PCT parameters consists of four steps:
1. Subtract baseline signal intensity (prior to contrast arrival) from
each CT image to obtain tissue time-enhancement curves Ct (t).
2. Select an input artery that supplies the brain to obtain the arterial
input function Ca (t).
3. Select a vein to correct partial volume averaging of the arterial
input function Ca (t) [4].
4. Calculate PCT parameters based on the chosen tracer kinetic
model of the software.
The different tracer kinetics models can be categorized as fol-
lows:
1. Model-independent method based on indicator dilution theory
that calculates BF and BV [5]. This is commonly used in dynamic
susceptibility-contrast MR  (DSC-MR). For brain tumor, the BV
obtained has to be corrected for contrast leakage as described by
Boxerman [6].
2. Compartmental model accounts for the rate of diffusional
exchange of contrast between the intravascular space and the
interstitial space (e.g. Ktrans) besides BV [7]. This is commonly
used in dynamic contrast-enhanced MR  (DCE-MR). Ktrans is the
product of BF and extraction efﬁciency (E) and when PS « BF, as
would be the case in brain tumor, it is equal to PS [8].
3. Distributed parameter model, which is commonly used in PCT,
calculates BF, BV, and rate of diffusional exchange (PS or Ktrans)
between blood and tissue [8]. Ktrans can then be calculated as
BF·(1 − exp(−PS/BF)) [8].
Here we describe the calculation of PCT parameters based on the
distributed parameter model ﬁrst proposed by Johnson and Wilson
and subsequently simpliﬁed by St Lawrence and Lee with their adi-
abatic approximation [9]. The tissue-enhancement curve Ct (t) can
be expressed as:
Ct(t) = BF · Ca(t) ⊗ R(t) (1)
where ⊗ is a convolution operator, and R(t) represents the impulse
residue function (IRF). Fig. 1 illustrates Eq. (1). The IRF describes the
fraction of contrast that remains in the tissue as time progresses,
following the injection of unit mass of contrast into the arterial
input. The product of the IRF and BF is called the BF-scaled IRF,
and it is solved by deconvolving the arterial input function Ca(t)
with the tissue enhancement curve Ct(t). The BF-scaled impulse
residue function has two  distinct phases (Fig. 1). The ﬁrst phase
describes the retention of contrast in the tissue prior to any venous
outﬂow; it has a peak height of BF (ml/min/100 g), a width that
equals to the mean transit time (MTT, s), and an area that equals to
BV (ml/100 g). The second phase describes the backﬂux of contrast
from the interstitial space into the bloodstream. It starts at a height
of the extraction fraction (E) and decays monoexponentially with
time. PS can be calculated as PS = − BF · ln (1 − E). PS is the unidi-
rectional diffusional ﬂux of contrast from the intravascular space
into the interstitial space across all “openings” of the permeable
capillary endothelium.
3. Clinical applications
3.1. Correlation with histopathologic markers and tumor grade
Angiogenesis is important for histopathologic grading of
gliomas by providing valuable information for treatment selections
and prediction of treatment response. Histopathologic grading of
gliomas using biopsied specimens can be prone to sampling error
due to the heterogeneity of tumors. It has been shown that 60%
of anaplastic astrocytomas (grade III) were upgraded to glioblas-
toma (grade IV) after comparing the biopsied specimens with the
resected tumors [10].
Microvascular density (MVD) and microvascular cellular prolif-
eration (MVCP) are histopathologic markers of angiogenesis. PCT
measures of BF and BV have shown signiﬁcant correlations with
MVD  (r = 0.527 and 0.649, respectively; P < 0.02), while PS showed
a signiﬁcant correlation with MVCP (r = 0.647, P = 0.001) [11]. These
results suggest that regions of higher angiogenic activities (i.e. more
aggressive) could be localized by maps of BF, BV, and PS to serve to
guide biopsy or resection. While statistically signiﬁcant, PCT cor-
relations with MVD  and MVCP were moderate, possibly because
MVD  and MVCP cannot fully reﬂect the complexity of tumor ves-
sels, which are tortuous and variable in size. MR perfusion measure
of relative BV (rBV) showed higher correlation with microvessel
area (MVA) than MVD  (r = 0.83 and 0.32, respectively; P ≤ 0.05) [12].
More importantly, MVA  and rBV correlated with overall survival
(OS) (P < 0.02) and MVD  did not (P = 0.17), suggesting rBV and MVA
could be superior to MVD  for predicting OS. MVA  can better reﬂect
the tortuosity and size of vessels, but MVA  is not measured rou-
tinely because it is time-consuming and labor-intensive. To date,
correlations between MVA  and PCT have not yet been reported.
Jain et al. explored the relationships between different PCT
parameters and the expression levels of genes associated with
angiogenesis in glioblastomas [13]. BV and/or PS correlated
positively with some proangiogenic genes (e.g. VEGFR-2) and neg-
atively with some anti-angiogenic genes (e.g. VASH2 and C3),
suggesting a molecular genetic basis for using PCT to assess
glioblastomas.
A number of studies have used PCT for tumor grading. In general,
PCT of HGGs (grade III and IV) demonstrated higher BF, BV, and PS
than low-grade gliomas (grade II) [11,14–22]. Figs. 2 and 3 illustrate
MR and PCT studies of patients with low-grade glioma and HGG,
respectively. Table 2 shows the reported sensitivities and speciﬁci-
ties of using PCT to differentiate HGGs versus low-grade gliomas.
PCT has also been reported to differentiate grade III from grade
IV gliomas with PS demonstrating better predictability than BV in
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Fig. 1. Graphical illustration showing how different CT perfusion parameters are calculated from a tissue enhancement curve Ct (t) and arterial input function Ca (t).
Fig. 2. A patient with grade II diffuse astrocytoma. Post-gadolinium T1-weighted image (A) shows a non-enhancing lesion (red and black arrows) with minimal peritumoral
edema on T2-weighted image (B). Maps of blood ﬂow (BF), blood volume (BV), and permeability-surface area product (PS) do not show a region of elevated BF, BV, and PS.
Fig. 3. A patient with grade IV glioblastoma. Post-gadolinium T1-weighted image (A) shows a contrast-enhancing tumor (red and black arrows) and substantial peritumoral
edema  on T2-weighted image (B). Maps of blood ﬂow (BF), blood volume (BV), and permeability-surface area product (PS) shows a rim with high BF, BV, and PS.
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Table 2
The performance of PCT in differentiating high vs. low grade gliomas.
Parameters Sensitivity ranges (%) Speciﬁcity ranges (%) References
BFa 71–91 82–100 [14,15,18,22]
BVa 83–100 75–100 [14,15,18,19,22]
PS 83 100 [19]
MTT  93 40 [18]
Ktrans 97 100 [14,22]
Abbreviations:  BF, blood ﬂow; BV, blood volume; PS, permeability-surface area prod-
uct; MTT, mean transit time; Ktrans , transfer constant.
a BF and BV refer to absolute values or absolute tumor BF and BV normalized to
BF and BV in the normal appearing white matter or contralateral brain region.
this regard (C-statistic = 0.926 and 0.787, respectively) [17]. This is
consistent with the correlation between PS and MVCP [11] in that
neovascularization is a criterion for diagnosing grade IV gliomas,
but not grade III gliomas, suggesting PS is sensitive to detecting
immature and leaky tumor vessels. In addition to grading, PS has
been shown to improve interobserver agreement of tumor bound-
ary delineation, which is particularly important for tumor targeting
by radiotherapy [23].
Up to 9% of HGGs are non-enhancing on post-gadolinium T1-
weighted MR,  which can be mistaken as low-grade gliomas [24].
Beppu et al. showed that PCT measurement of BV could differen-
tiate non-enhancing grade III gliomas from grade II gliomas with
a sensitivity and speciﬁcity of 90.9% and 83.3%, respectively [15].
All these studies support the use of PCT as a noninvasive surro-
gate of tumor grade, which can potentially be used to guide biopsy
and resection of gliomas and potentially avoid under-grading non-
enhancing HGGs.
3.2. Differentiation of high-grade gliomas from other brain lesions
There are non-malignant and malignant lesions that can appear
similar to HGGs on contrast-enhanced MR  images. Tumefactive
demyelinating lesions (TDLs) are solitary lesions greater than 2 cm
that mimic  HGGs on contrast-enhanced MR  images [25], and can
also be confused with HGGs on histopathology [26]. Differentiation
of TDLs from HGGs may  avoid unnecessary biopsy and resection of
viable brain tissue. Using PCT, TDLs showed signiﬁcantly lower BF,
BV, and PS than HGGs [27]. These results are consistent with the
observations that TDLs are characterized by normal or inﬂamed
vessels and a lack of vascular proliferation while the latter is com-
mon  in HGGs [26].
Primary brain lymphomas, brain metastases, and HGGs are
malignant lesions that can appear similar to each other on MR
images. HGGs showed signiﬁcantly higher BV and BF than primary
brain lymphomas, suggesting PCT may  have utility in differentiat-
ing the two entities [22,28]. However, Fainardi et al. showed that
there was no signiﬁcant difference in tumor BV and PS between
HGGs and metastases [16]. Previous DSC-MR studies showed that
tumor BV values from brain metastases were either similar to
or lower than HGGs [29,30]. Thus, it may  be difﬁcult to distin-
guish metastases from HGGs using tumor BV. DSC-MR studies
that focused on the peritumoral edema regions of tumors (hyper-
intense regions on T2-weighted MR)  found that BV values in
these regions were signiﬁcantly higher in HGGs than brain metas-
tases [30,31]. This observation suggests a possibility to distinguish
HGG and brain metastases by evaluating BV in the peritumoral
edema region. The high BV in the peritumoral edema region of
HGG could be attributed to its inﬁltrative growth while tumor
inﬁltration is not a characteristic feature of brain metastasis
[32].
Table 3
Differentiation of treatment-induced necrosis from true progression of brain
tumors.
Parameters Sensitivity ranges (%) Speciﬁcity ranges (%) References
aRelative BF 94% 88% [38]
aRelative BV 71–83% 90–100% [38–40]
PS 82% 82% [39]
Relative MTT  94% 75% [38]
Abbreviations:  BF, blood ﬂow; BV, blood volume; PS, permeability-surface area prod-
uct; MTT, mean transit time.
a Relative BF and BV refer to absolute tumor BF and BV normalized to BF and BV
in  the normal appearing white matter or contralateral brain region.
3.3. Differentiation of true progression from post-treatment
effects
An increase in the size of the contrast-enhancing tumor is
a radiologic measure of progression, but the effects of radio-
therapy can also mimic the appearance of true progression
on contrast-enhanced MR  images [33]. Pseudoprogression and
treatment-induced necrosis (TIN) are two post-radiotherapy sce-
narios that mimic  true progression on MR.  It is imperative to
differentiate these entities accurately since they are managed dif-
ferently.
Although the mechanism of pseudoprogression is unclear, it is
believed to be induced by a local inﬂammatory reaction, edema,
and increased vessel permeability that lead to contrast enhance-
ment on imaging [33]. Previous DSC-MR studies showed that true
progression had signiﬁcantly higher relative BV (rBV) than pseu-
doprogression [34,35] and TIN [36,37]. Using PCT, true progression
showed signiﬁcantly higher values of rBF, rBV, and PS than TIN
[38–40]. Sensitivities and speciﬁcities of >80% were measured using
PCT to differentiate true progression from TIN in brain tumors
(Table 3). Fig. 4 shows a PCT study of a patient with progres-
sion 6 months after radiotherapy, and Fig. 5 shows a patient with
histopathologically conﬁrmed radiation necrosis 3 months after
radiotherapy.
PCT offers an advantage over MR  perfusion in this regard since it
can measure all three vascular parameters—BF, BV and PS, which is
technically challenging for DSC-MR and DCE-MR. True progressive
brain tumors are malignancies with increased vascularity, imma-
ture leaky vessels, and upregulated VEGF expression resulting in
higher BF, BV and PS. On the other hand, the moderate PS observed
in TIN is likely mediated by the release of VEGF in the pathogen-
esis of radiation necrosis [41]. In addition, susceptibility artefacts
from blood products (hemorrhage, thrombus) and calciﬁcation can
potentially complicate the analysis of DSC-MR studies while PCT is
not affected by these artefacts [39,42].
3.4. Prediction of prognosis
Recently, PCT parameters have been used to predict overall sur-
vival (OS) after surgery/biopsy, radiotherapy, and temozolomide
chemotherapy. Pre-treatment PCT exams showed that tumor rel-
ative BV alone [43], PS alone [44], and relative BV + PS were all
predictive of OS [43,44]. More importantly, rBV alone and rBV + PS
remained signiﬁcant predictors of OS even after adjusting for clas-
sical prognostic factors (age, Karnofsky performance status, extent
of resection, and grade) [43], suggesting that PCT parameters could
improve the prediction of OS.
Local recurrence within 2 cm of the irradiated volume predom-
inates post-radiotherapy, making imaging assessments of both the
contrast-enhancing tumor and the peritumoral edema region crit-
ical [45]. Yeung et al. showed that patients with shorter OS  had
higher BV and PS in both regions than patients with longer OS
(Fig. 6), and that post-radiotherapy BV in the peritumoral edema
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Fig. 4. A patient who  was  previously treated for a glioblastoma multiforme shows a progressive enhancing lesion (T1-weighted MR)  with high blood ﬂow (BF), blood volume
(BV),  and permeability-surface area product (PS) suggesting progressive tumor around the surgical cavity at 6 months post-radiotherapy.
Fig. 5. A patient with histopathologically conﬁrmed radiation necrosis shows a progressive enhancing lesion (T1-weighted MR)  with low blood ﬂow (BF), blood volume (BV),
and  permeability-surface area product (PS).
region could predict 24 months OS with sensitivities and speciﬁci-
ties >80% [46]. Similar results have been demonstrated in DSC-MR
studies [47,48]. These ﬁndings highlight the importance of paying
attention to the peritumoral edema region. Radiotherapy targeting
of the peritumoral edema region with PCT image-guidance may  be a
viable option that is worth exploring. PCT can play an important role
in radiation oncology since CT imaging is required for radiotherapy
treatment planning.
4. Discussion: strengths and challenges of PCT
DSC-MR is currently the most commonly used perfusion imag-
ing technique for assessing brain tumors. However, PCT has several
advantages that make it a useful alternative functional imaging
tool. The linear relationship between signal intensity (HU) and
iodine concentration is a major strength of PCT. DSC-MR with
T2 or T2*-weighting is prone to two types of artefacts. DSC-MR
Fig. 6. CT perfusion and MR images of patients with glioblastomas. Both patients presented with a contrast-enhancing tumor (red and black arrows) on post-gadolinium
T1-weighted MR images that had high blood ﬂow (BF), blood volume (BV), and permeability-surface area product (PS). Patient A also presented with regions of high BF, BV,
and  outside the contrast-enhancing tumor (red and black asterisks). Survival for Patient A was 16.7 months. Patient B presented with low BF, BV, and PS in the peritumoral
region outside the contrast-enhancing tumor (red and black asterisks). Survival for patient B was  41.6 months.
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measurement of BV depends on the compartmentalization of
contrast within blood vessels. In brain tumors where consider-
able amount of contrast can leak into the interstitial space, the
susceptibility-contrast signal intensity loss can be masked by the
competing T1 effects [6]. DSC-MR measurement leads to an under-
estimation of BV if it is not addressed by (1) pre-saturating the brain
parenchyma with a pre-loading dose of contrast, (2) dual-echo
sequence, or (3) post-processing correction [6,42]. This effect also
makes the quantiﬁcation of tumor permeability technically chal-
lenging. In addition, the susceptibility artefacts created by blood
products (from hemorrhage and thrombus) in tumors are other
factors that can affect the quantiﬁcation of BV. PCT is clearly advan-
tageous in this respect.
The second major advantage of PCT is the capability to mea-
sure BF, BV, and PS from a single scan. The measurements of BF
and BV require rapid image acquisitions (1–2 s per image), which is
technically challenging for T1-weighted DCE-MR. For DSC-MR, the
effect of contrast extravasation on signal intensity makes the cal-
culation of PS difﬁcult to achieve as discussed above. Furthermore,
measuring the arterial input function needed for calculating abso-
lute values of BF and BV is problematic with MR  perfusion due to
the trade-off between spatial and temporal resolutions. The high
spatial and temporal resolutions of CT scanning and the linearity
between iodine concentration and CT image intensity enable the
calculation of BF, BV, and PS from a single PCT study.
MR is the standard of care for brain tumor patients; hence,
the follow-up of patients with MR  perfusion is more convenient
than PCT as perfusion imaging can be included as part of a single
multi-parametric MR  study. The clinical use of PCT has also been
slow to progress due to two major limitations. Radiation dose is of
concern when performing a PCT scan. The effective doses with cur-
rent techniques are between 2.5 and 5.5 mSv  for tube currents of
100–190 mA  [49]. Recent advances in adaptive statistical iterative
reconstruction can reduce imaging dose without compromising the
diagnostic acceptability [50]. An image ﬁltering technique called
principal component analysis can also improve PCT image quality;
thereby presenting another opportunity for further dose reduction
[51]. The limited scan coverage (2–4 cm coverage) is another limi-
tation of PCT, making whole tumor assessment difﬁcult. However,
the advent of shuttle mode imaging and large multi-row detector
technology enables whole brain PCT coverage [52,53]. Differences
in PCT protocol (e.g. PCT scan duration) and calculation software
could lead to disagreements in the values of PCT parameters [49,54].
Therefore, standardization of PCT protocol and software are critical
for cross-study comparison.
5. Conclusions
PCT can provide tumor hemodynamics information for pre-
operative tumor grading, response assessment, and OS prediction.
Results from PCT studies are comparable to those performed with
MR perfusion. PCT is technically less demanding than MR  perfusion
and provides measurements of BF, BV, and PS from a single scan.
The obstacles of limited scan coverage and radiation dose are being
addressed by recent advances in CT imaging. In our opinion, PCT has
reached sufﬁcient technical maturity for use as a routine functional
imaging tool for brain tumor assessment.
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